GBT Announces New Employment Inducement Grants
November 09 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that on November 1, 2020, the compensation committee
of GBT’s board of directors granted 10 new employees options to
purchase an aggregate of 19,500 shares of the company’s common
stock with a per share exercise price of $52.88 and restricted
stock units for an aggregate of 89,675 shares of the company’s
common stock. These awards were made under GBT’s Amended and
Restated 2017 Inducement Equity Plan (the Plan). Pursuant to the
Plan, the exercise price for the 19,500 shares of the company’s
common stock was the closing trading price on October 30, 2020,
because there was no closing trading price on November 1, 2020.
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to
the discovery, development, and delivery of life-changing
treatments that provide hope to underserved patient communities.
Founded in 2011, GBT is delivering on its goal to transform the
treatment and care of sickle cell disease (SCD), a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved treatment that
directly inhibits sickle hemoglobin polymerization, the root cause
of red blood cell sickling in SCD. GBT is also advancing its
pipeline program in SCD with inclacumab, a P-selectin inhibitor in
development to address pain crises associated with the disease, and
GBT021601, the company’s next generation hemoglobin S
polymerization inhibitor. In addition, GBT’s drug discovery teams
are working on new targets to develop the next wave of treatments
for SCD. To learn more, please visit www.gbt.com and
follow the company on Twitter @GBT_news.
Contact Information:Steven Immergut (investors
and media)650-410-3258simmergut@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024